



JC04 Rec'd PCT/PTO 18 OCT 2005  
PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application

Examiner:

Michael GIESING et al.

Group Art Unit:

Application Number: 10/525,019

Confirmation No.: 4832

Filed: February 18, 2005

Attorney Docket No.: GIES3002

For: METHOD FOR ANALYZING BODY FLUIDS FOR THE PRESENCE OF  
CANCER CELLS, USE THEREOF, CORRESPONDING ANALYSIS KITS, AND  
USE OF SPECIFIC ACTIVE SUBSTANCES FOR TREATING CANCER

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to Rule 37 C.F.R. §1.51(b), §1.56, §1.97, and §1.98, this Information Disclosure Statement is submitted in the above-identified patent application. A listing of documents to be published on the face of any patent granted from this application is submitted herewith on Form PTO-1449. Any other documents or information submitted for consideration by the Examiner are listed in this paper. A copy of each U.S. and foreign patent, or each publication or portion thereof listed or herein identified is submitted herewith.

**STATEMENT OF TIMELINESS**

This Information Disclosure Statement is submitted prior to the mailing date of the first Office Action on the merits received by Applicant in the above-identified application.

Serial Number: 10/525,019  
Attorney Docket: GIES3002

The Examiner is requested to acknowledge consideration of the information provided in this paper in accordance with prescribed procedures.

Respectfully submitted,  
BACON & THOMAS, PLLC

By:

  
Eric S. Spector

Registration No. 22,495

BACON & THOMAS, PLLC

Customer 23364  
625 Slaters Lane - 4<sup>th</sup> Floor  
Alexandria, VA 22314-1176  
Telephone: (703) 683-0500  
Facsimile: (703) 683-1080

Date: October 18, 2005



Customer 23364  
Sheet 1 of 3

|   |  |                                    |
|---|--|------------------------------------|
| B/O Form PTO-1449<br><br>U.S. Department of Commerce<br>Patent and Trademark Office<br><br>Information Disclosure Statement by<br>Applicant | Atty. Docket Number<br><b>GIES3002</b>     | Serial Number<br><b>10/525,019</b> |
|   | Applicant<br><b>Michael GIESING et al.</b> |                                    |
|   | Filing Date<br><b>February 18, 2005</b>    | Group                              |

### U.S. Patent Documents

| Examiner Initial | Document Number | Date       | Patentee/Applicant      | Class | Subclass | Filing Date if Appropriate |
|------------------|-----------------|------------|-------------------------|-------|----------|----------------------------|
|                  | 5,246,847       | 09/21/1993 | Jacob R. Hartman et al. | 435   | 189      | 02/27/1992                 |
|                  | 5,260,204       | 11/09/1993 | Konrad Heckl et al.     | 435   | 189      | 09/15/1992                 |
|                  | 5,985,633       | 11/16/1999 | Harry S. Nick et al.    | 435   | 189      | 09/10/1997                 |
|                  | 2003/0157581    | 08/21/2003 | Hans-Horg Grill et al.  | 435   | 8        |                            |

### Foreign Patent Documents

| Examiner Initial | Document Number | Publication Date | Country/Agency | Class | Subclass | Translation |    |
|------------------|-----------------|------------------|----------------|-------|----------|-------------|----|
|                  |                 |                  |                |       |          | Yes         | No |
|                  | 2,301,962       | 03/04/1999       | Canada         |       |          |             | X  |
|                  | 2,338,751       | 02/10/2000       | Canada         |       |          | X           |    |
|                  | 100 54 632 A1   | 05/29/2002       | Germany        |       |          |             | X  |
|                  | WO 96/29430     | 09/26/1996       | PCT            |       |          | X           |    |
|                  | WO 02/18634 A2  | 03/07/2002       | PCT            |       |          | X           |    |

### Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)

|  |  |
|--|--|
|  | SARTO, C., et al., "Modified Expression of Plasma Glutathione Peroxidase and Manganese Superoxide Dismutase in Human Renal Cell Carcinoma", Electrophoresis 1999, 20, 3458-3466  |
|  | BOER, J.M., et al., "Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA Array", Genome Research, www.genome.org, 11:1861-1870, 2001                         |
|  | MORK, H., et al., "Inverse mRNA Expression of the Selenocysteine-Containing Proteins GI-GPx and SeP Colorectal Adenomas Compared With Adjacent Normal Mucosa", Nutrition and Cancer, 37(1), 108-116, 2000  |
|  | SARTO, C., et al., "Renal Cell Carcinoma and Normal Kidney Protein Expression", Electrophoresis 1997, 18, 599-604  |
|  | GLADYSHEV, V.N., et al., "Contrasting Patterns of Regulation of the Antioxidant Selenoproteins, Thioredoxin Reductase, and Glutathione Peroxidase, in Cancer Cells", Biochemical and Biophysical Research Communications, 251, 488-493 (1998) Article No. RC989495 |
|  | BRAVARD, A., et al., "Modifications of the Antioxidant Enzymes in Relation to Chromosome Imbalances in Human Melanoma Cell Lines", Melanoma Research 1998, 8, pp. 329-335  |
|  | PESKIN, A. V., et al., "Superoxide Dismutase and Glutathione Peroxidase Activities in Tumors", FEBS LETTERS, Vol. 78, No. 1, June 1977, 41-45  |
|  | KAHLOS, K., et al., "Manganese Superoxide Dismutase in Healthy Human Pleural Mesothelium and in Malignant Pleural Mesothelioma", Am. J. Respir. Cell Mol. Biol., Vol. 18, pp. 570-580, 1998  |
|  | DVORAKOVA, K., "Molecular and Cellular Characterization of Imuron-Resistant RPMI8226/I Myeloma Cells", Molecular Cancer Therapeutics, Vol. 1, p. 185-195, January 2002   |

|          |                 |
|----------|-----------------|
| Examiner | Date Considered |
|----------|-----------------|

**EXAMINER:** Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



|   |  |  |                                    |
|---|--|--|------------------------------------|
| B/O Form PTO-1449<br>U.S. Department of Commerce<br>Patent and Trademark Office<br>Information Disclosure Statement by<br>Applicant |  | Atty. Docket Number<br><b>GIES3002</b>     | Serial Number<br><b>10/525,019</b> |
|   |  | Applicant<br><b>Michael GIESING et al.</b> |                                    |
|   |  | Filing Date<br><b>February 18, 2005</b>    | Group                              |

**Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)**

|  |   |
|--|---|
|  | ASIKAINEN, T.M., et al., "Expression and Developmental Profile of Antioxidant Enzymes in Human Lung and Liver", A. J. Respir. Cell Mol. Biol., Vol. 19, pp. 942-949, 1998   |
|  | LI, Z., et al., "Genes Regulated in Human Breast Cancer Cells Overexpressing Manganese-Containing Superoxide Dismutase", Free Radical Biology & Medicine, Vol. 30, No. 3, pp. 260-267, 2001   |
|  | MERCATANTE, K.R., et al., "Control of Alternative Splicing by Antisense Oligonucleotides as a Potential Chemotherapy: Effects on Gene Expression", Biochem & Biophys Acta, 2002, July 18, 1587 (2-3): 126- 132  |
|  | JANSSEN, AML, et al., "Superoxide Dismutases in Relation to the Overall Survival of Colorectal Cancer Patients", British Journal of Cancer (1998) 78(8), 1051-1057  |
|  | JANSEEN, AML, et al., "Superoxide Dismutases in Gastric and Esophageal Cancer and the Prognostic Impact in Gastric Cancer", Clinical Cancer Research, Vol. 6, 3183-3192, August 2000  |
|  | RIA, F., et al., "The Level of Manganese Superoxide Dismutase Content is an Independent Prognostic Factor for Glioblastoma Biological Mechanisms and Clinical Implications", British Journal of Cancer (2001) 84(4), 529-534  |
|  | GIESING, M., et al., "Independent Prognostication and Therapy Monitoring of Breast Cancer Patients by DNA/RNA typing of Minimal Residual Cancer Cells", The International Journal of Biological Markers, Vol. 15, No. 1, pp. 94-99                                      |
|  | BARRA, D., et al., "The Primary Structure of Human Liver Manganese Superoxide Dismutase", The Journal of Biological Chemistry, Vol. 259, No. 20, Issue of Oct. 25, 12595-12601, 1984  |
|  | "GeneChip® Human Genome U133 Set, Comprehensive Coverage of All Well-Substantiated Genes in the Human Genome", Gene Expression Monitoring, Affymetrix, printed 1-21-2002, pages 1-2   |
|  | STOEHLMACHER, J., et al., "The -9 Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma", Oncol. Rep., 2002 Mar-Apr, 9(2):235-8 (Abstract) |
|  | FORSBERG, L., et al., "Low yield of polymorphisms from EST blast searching: analysis of genes related to oxidative stress and verification of the P197L polymorphism in GPX1", Hum. Mutat. 1999, 13(4):294-300 (Abstract)   |
|  | LI, S., et al., "The Role of Cellular Glutathione Peroxidase Redox Regulation in the Suppression of Tumor Cell Growth by Manganese Superoxide Dismutase", Cancer Research 60, 3927-3939, July 15, 2000 (Abstract)   |
|  | SODERBERG, A., et al., "Thioredoxin Reductase, a Redox-active Selenoprotein, Is Secreted by Normal and Neoplastic Cells: Presence in Human Plasma", Cancer Research 60, 2281-2289, April 15, 2000 (Abstract)  |
|  | BECKER, K., et al. "Thioredoxin reductase as a pathophysiological factor and drug target", Eur. J. Biochem. 267, 6118-6125 (2000) (Abstract)  |
|  | SOINI, Y., et al., "MnSOD expression is less frequent in tumour cells of invasive breast carcinomas than in <i>in situ</i> carcinomas or non-neoplastic breast epithelial cells", J. Pathol. 2001 Sept, 195(2):156-62 (Abstract)  |
|  |   |

|          |                 |
|----------|-----------------|
| Examiner | Date Considered |
|----------|-----------------|

**EXAMINER:** Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Customer 23364  
Sheet 3 of 3

|  |  |  |               |
|--|--|--|---------------|
| B/O Form PTO-1449  |  | Atty. Docket Number                        | Serial Number |
|  |  | GIES3002                                   | 10/525,019    |
| U.S. Department of Commerce<br>Patent and Trademark Office |  | Applicant<br><b>Michael GIESING et al.</b> |               |
| Information Disclosure Statement by Applicant              |  | Filing Date<br><b>February 18, 2005</b>    | Group         |

**Other Documents (Including Author, Title, Date, Pertinent Pages, Place of Publication, Etc.)**

*Examiner* \_\_\_\_\_ *Date Considered* \_\_\_\_\_

*EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP 609; Draw a line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*